FOXA1 and cancer: However, the non basal-like AR+ FOXA1+ CK14– subgroup was associated with longer disease-free interval (p = 0.011, Fig. 4a) and longer cancer-specific survival (HR = 0.33, 95% CI: 0.15–0.70, p = 0.043; Fig. 4b) by univariate survival analysis compared to the basal-like AR+ FOXA1– CK14+ subgroup that was associated with a worse outcome.